2001
DOI: 10.1016/s0006-2952(00)00576-1
|View full text |Cite
|
Sign up to set email alerts
|

Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
113
0
1

Year Published

2003
2003
2016
2016

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 123 publications
(115 citation statements)
references
References 67 publications
1
113
0
1
Order By: Relevance
“…Our data are consistent with published work [3] that suggests inhibition of mucosal cyclooxygenase (COX) and loss of protective prostaglandins (PG) are insufficient to explain NSAID effects on epithelial restitution. The COX-2 antagonist NS-398 and the non-specific COX anatagonist indomethacin impeded intestinal epithelial cell migration, whereas the COX-1 antagonist SC-560 did not.…”
Section: Discussionsupporting
confidence: 92%
See 3 more Smart Citations
“…Our data are consistent with published work [3] that suggests inhibition of mucosal cyclooxygenase (COX) and loss of protective prostaglandins (PG) are insufficient to explain NSAID effects on epithelial restitution. The COX-2 antagonist NS-398 and the non-specific COX anatagonist indomethacin impeded intestinal epithelial cell migration, whereas the COX-1 antagonist SC-560 did not.…”
Section: Discussionsupporting
confidence: 92%
“…Adverse GI effects of NSAIDs including GI ulceration [1][2][3][4] result in 100,000 emergency admissions, high medical costs and 17,500 deaths per year in the US alone [5,6]. Despite extensive investigation, the mechanisms responsible for NSAID-associated GI damage are incompletely understood.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…The mechanism by which aspirin and related NSAIDs injure the GI mucosa was once thought to be strictly due to disruption of the biosynthesis of cytoprotective prostaglandins via inhibition of constitutive cyclooxygenase-1 (COX-1) [19], leading to the development of highly selective COX-2 inhibitors (coxibs) as safer anti-inflammatory drugs. However, over time this concept has been challenged, with the demonstration that NSAIDs can induce GI injury by COX-independent mechanisms [20], and the demonstration that a number of highly selective coxibs have unanticipated and potentially life-threatening cardiovascular, renal, and hepatic side effects [21], eventuating in their withdrawal from the US market.…”
mentioning
confidence: 99%